BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24446275)

  • 1. Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?
    Ceelen F; Theisen D; de Albéniz XG; Auernhammer CJ; Haug AR; D'Anastasi M; Paprottka PM; Rist C; Reiser MF; Sommer WH
    J Magn Reson Imaging; 2015 Feb; 41(2):361-8. PubMed ID: 24446275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
    Peker A; Çiçek O; Soydal Ç; Küçük NÖ; Bilgiç S
    Diagn Interv Radiol; 2015; 21(1):54-9. PubMed ID: 25430526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
    King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
    Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
    Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
    Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
    Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients.
    Klingenstein A; Haug AR; Zech CJ; Schaller UC
    Cardiovasc Intervent Radiol; 2013 Feb; 36(1):158-65. PubMed ID: 22526099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.
    Michl M; Lehner S; Paprottka PM; Ilhan H; Bartenstein P; Heinemann V; Boeck S; Albert NL; Fendler WP
    J Nucl Med; 2016 Mar; 57(3):355-60. PubMed ID: 26609176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
    Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
    Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases.
    Cao CQ; Yan TD; Bester L; Liauw W; Morris DL
    Br J Surg; 2010 Apr; 97(4):537-43. PubMed ID: 20205229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.
    Filippi L; Scopinaro F; Pelle G; Cianni R; Salvatori R; Schillaci O; Bagni O
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):432-40. PubMed ID: 26323577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis.
    Ludwig JM; Ambinder EM; Ghodadra A; Xing M; Prajapati HJ; Kim HS
    Cardiovasc Intervent Radiol; 2016 Jul; 39(7):1007-14. PubMed ID: 26964779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
    Sato KT; Lewandowski RJ; Mulcahy MF; Atassi B; Ryu RK; Gates VL; Nemcek AA; Barakat O; Benson A; Mandal R; Talamonti M; Wong CY; Miller FH; Newman SB; Shaw JM; Thurston KG; Omary RA; Salem R
    Radiology; 2008 May; 247(2):507-15. PubMed ID: 18349311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis.
    Devcic Z; Rosenberg J; Braat AJ; Techasith T; Banerjee A; Sze DY; Lam MG
    J Nucl Med; 2014 Sep; 55(9):1404-10. PubMed ID: 25012459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.